Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Deloitte
Medtronic
Teva
Daiichi Sankyo
Healthtrust
Baxter
Moodys
Chubb

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204708

« Back to Dashboard

NDA 204708 describes MIRVASO, which is a drug marketed by Galderma Labs Lp and is included in one NDA. It is available from one supplier. There are eleven patents protecting this drug and one Paragraph IV challenge. Additional details are available on the MIRVASO profile page.

The generic ingredient in MIRVASO is brimonidine tartrate. There are eleven drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the brimonidine tartrate profile page.
Summary for 204708
Tradename:MIRVASO
Applicant:Galderma Labs Lp
Ingredient:brimonidine tartrate
Patents:11
Therapeutic Class:Ophthalmic Agents
Pharmacology for NDA: 204708
Mechanism of ActionAdrenergic alpha-Agonists
Medical Subject Heading (MeSH) Categories for 204708
Suppliers and Packaging for NDA: 204708
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MIRVASO brimonidine tartrate GEL;TOPICAL 204708 NDA Galderma Laboratories, L.P. 0299-5980 N 0299-5980-00
MIRVASO brimonidine tartrate GEL;TOPICAL 204708 NDA Galderma Laboratories, L.P. 0299-5980 N 0299-5980-02

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:GEL;TOPICALStrengthEQ 0.33% BASE
Approval Date:Aug 23, 2013TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Aug 25, 2025Product Flag?Substance Flag?Delist Request?
Patented Use:TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
Patent:➤ Try a Free TrialPatent Expiration:Jun 13, 2031Product Flag?YSubstance Flag?Delist Request?
Patented Use:TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
Patent:➤ Try a Free TrialPatent Expiration:Jun 13, 2031Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Federal Trade Commission
McKinsey
UBS
Cipla
Cerilliant
Harvard Business School
US Department of Justice
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.